Comparison liver resection with transarterial chemoembolization for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma patients on long-term survival after SPSS propensity score matching

National Medical Journal of China

Volumn 94, Issue 10, 2014, Pages 747-750

  Ke, Yang ^a   Zhong, Jianhong ^a   Guo, Zhe ^a   Liang, Yongrong ^a   Li, Lequn ^a   Xiang, Bangde ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Carcinoma, hepatocellular; Chemoembolization, therapeutic; Hepatectomy; Propensity score; Survival rate

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN;

ARTICLE; BARCELONA CLINIC LIVER CANCER STAGE B; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPARATIVE STUDY; COMPUTER PROGRAM; CONTROLLED STUDY; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; ONCOLOGICAL PARAMETERS; PROPENSITY SCORE; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR NUMBER;

EID: 84898914396     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2014.10.007     Document Type: Article

References (16)

1. 2010, 31: 347-348.
2. 2011, 28: 89-92.
3. Forner A, Llovet J M, Bruix J. Hepatocellular carcinoma [J]. Lancet, 2012, 379: 1245-1255.
4. Ho M C, Huang G T, Tsang Y M, et al. Liver resection improves the survival of patients with multiple hepatocellular carcinomas [J]. Ann Surg Oncol, 2009, 16: 848-855.
5. Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma [J]. Gastroenterology, 2008, 134: 1908-1916.
6. Ruzzenente A, Capra F, Pachera S, et al. Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients [J]. J Gastrointest Surg, 2009, 13: 1313-1320.
7. Lin C T, Hsu K F, Chen T W, et al. Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice[J]. World J Surg, 2010, 34:2155-2161.
8. Wang J H, Changchien C S, Hu T H, et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma-Survival analysis of 3892 patients[J]. Eur J Cancer, 2008, 44: 1000-1006.
9. 2011, 27: 1141-1159.
10. Rosenbaum P R, Rubin D B. The central role of propensity score in observational studies for causal effects [J]. Biometrika, 1983, 70: 16.
11. Su C W, Lei H J, Chau G Y, et al. The effect of age on the long-term prognosis of patients with hepatocellular carcinoma after resection surgery: a propensity score matching analysis [J]. Arch Surg, 2012, 147: 137-144.
12. 2013, 19:23-28.
13. 2003, 83: 1053-1057.
14. 2012, 92: 3185-3186.
15. Kao W Y, Chiou Y Y, Hung H H, et al. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy [J]. Clin Radiol, 2012, 67: 429-436.
16. Kuzuya T, Asahina Y, Tsuchiya K, et al. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma [J]. Oncology, 2011, 81:251-258.